187 related articles for article (PubMed ID: 24647786)
1. Rapid strategy for screening by pyrosequencing of influenza virus reassortants--candidates for live attenuated vaccines.
Shcherbik SV; Pearce NC; Levine ML; Klimov AI; Villanueva JM; Bousse TL
PLoS One; 2014; 9(3):e92580. PubMed ID: 24647786
[TBL] [Abstract][Full Text] [Related]
2. Generation and Characterization of Live Attenuated Influenza A(H7N9) Candidate Vaccine Virus Based on Russian Donor of Attenuation.
Shcherbik S; Pearce N; Balish A; Jones J; Thor S; Davis CT; Pearce M; Tumpey T; Cureton D; Chen LM; Villanueva J; Bousse TL
PLoS One; 2015; 10(9):e0138951. PubMed ID: 26405798
[TBL] [Abstract][Full Text] [Related]
3. [Peculiarity of reassortment of current wild type influenza viruses with master donor viruses for live influenza vaccine].
Kiseleva IV; Bazhenova EA; Larionova NV; Fedorova EA; Dubrovina IA; Isakova-Sivak IN; Rudenko LG
Vopr Virusol; 2013; 58(5):26-31. PubMed ID: 24640168
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibody against N2 neuraminidase of cold adapted A/Leningrad/134/17/57 (H2N2) enables efficient generation of live attenuated influenza vaccines.
Shcherbik S; Carney P; Pearce N; Stevens J; Dugan VG; Wentworth DE; Bousse T
Virology; 2018 Sep; 522():65-72. PubMed ID: 30014859
[TBL] [Abstract][Full Text] [Related]
5. [Genome composition analysis of the reassortant influenza viruses used in seasonal and pandemic live attenuated influenza vaccine].
Kiseleva IV; Voeten JT; Teley LC; Larionova NV; Dubrovina IA; Berdygulova ZhA; Bazhenova EA; van den Bosch H; Heldens JG; Rudenko LG
Mol Gen Mikrobiol Virusol; 2011; (4):29-36. PubMed ID: 22312898
[TBL] [Abstract][Full Text] [Related]
6. Genetic stability of live attenuated vaccines against potentially pandemic influenza viruses.
Kiseleva I; Dubrovina I; Fedorova E; Larionova N; Isakova-Sivak I; Bazhenova E; Pisareva M; Kuznetsova V; Flores J; Rudenko L
Vaccine; 2015 Dec; 33(49):7008-14. PubMed ID: 26432909
[TBL] [Abstract][Full Text] [Related]
7. Safety, immunogenicity and protection of A(H3N2) live attenuated influenza vaccines containing wild-type nucleoprotein in a ferret model.
Korenkov DA; Laurie KL; Reading PC; Carolan LA; Chan KF; Isakova-Sivak II; Smolonogina TA; Subbarao K; Barr IG; Villanueva J; Shcherbik S; Bousse T; Rudenko LG
Infect Genet Evol; 2018 Oct; 64():95-104. PubMed ID: 29929009
[TBL] [Abstract][Full Text] [Related]
8. [Contribution of neuraminidase of influenza viruses to the sensitivity to the serum inhibitors and reassortment efficiency].
Kiseleva IV; Larionova NV; Bazhenova EA; Fedeorova EA; Dubrovina IA; Isakova-Sivak IN; Rudenko LG
Mol Gen Mikrobiol Virusol; 2014; (3):34-40. PubMed ID: 25335411
[TBL] [Abstract][Full Text] [Related]
9. Generation and characterization of a cold-adapted attenuated live H3N2 subtype influenza virus vaccine candidate.
An WQ; Yang PH; Duan YQ; Luo DY; Tang C; Jia WH; Xing L; Shi XF; Zhang YJ; Liu XF; Wang XL
Chin Med J (Engl); 2009 Dec; 122(23):2880-5. PubMed ID: 20092795
[TBL] [Abstract][Full Text] [Related]
10. A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus.
Smith A; Rodriguez L; El Ghouayel M; Nogales A; Chamberlain JM; Sortino K; Reilly E; Feng C; Topham DJ; Martínez-Sobrido L; Dewhurst S
J Virol; 2020 Jan; 94(4):. PubMed ID: 31748399
[TBL] [Abstract][Full Text] [Related]
11. Application of real time RT-PCR for the genetic homogeneity and stability tests of the seed candidates for live attenuated influenza vaccine production.
Shcherbik S; Sergent SB; Davis WG; Shu B; Barnes J; Kiseleva I; Larionova N; Klimov A; Bousse T
J Virol Methods; 2014 Jan; 195():18-25. PubMed ID: 24056261
[TBL] [Abstract][Full Text] [Related]
12. [Restriction analysis of genome composition of live influenza vaccine].
Kiseleva IV; Larionova NV; Teley LC; Rudenko LG
Vopr Virusol; 2011; 56(3):28-32. PubMed ID: 21786624
[TBL] [Abstract][Full Text] [Related]
13. Implementation of new approaches for generating conventional reassortants for live attenuated influenza vaccine based on Russian master donor viruses.
Shcherbik S; Pearce N; Kiseleva I; Larionova N; Rudenko L; Xu X; Wentworth DE; Bousse T
J Virol Methods; 2016 Jan; 227():33-9. PubMed ID: 26519883
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic properties resulting from directed gene segment reassortment between wild-type A/Sydney/5/97 influenza virus and the live attenuated vaccine strain.
Parks CL; Latham T; Cahill A; O'neill RE; Passarotti CJ; Buonagurio DA; Bechert TM; D'Arco GA; Neumann G; Destefano J; Arendt HE; Obregon J; Shutyak L; Hamm S; Sidhu MS; Zamb TJ; Udem SA
Virology; 2007 Oct; 367(2):275-87. PubMed ID: 17599381
[TBL] [Abstract][Full Text] [Related]
15. Master donor viruses A/Leningrad/134/17/57 (H2N2) and B/USSR/60/69 and derived reassortants used in live attenuated influenza vaccine (LAIV) do not display neurovirulent properties in a mouse model.
Voeten JT; Kiseleva IV; Glansbeek HL; Basten SM; Drieszen-van der Cruijsen SK; Rudenko LG; van den Bosch H; Heldens JG
Arch Virol; 2010 Sep; 155(9):1391-9. PubMed ID: 20532926
[TBL] [Abstract][Full Text] [Related]
16. Modifications in the polymerase genes of a swine-like triple-reassortant influenza virus to generate live attenuated vaccines against 2009 pandemic H1N1 viruses.
Pena L; Vincent AL; Ye J; Ciacci-Zanella JR; Angel M; Lorusso A; Gauger PC; Janke BH; Loving CL; Perez DR
J Virol; 2011 Jan; 85(1):456-69. PubMed ID: 20962084
[TBL] [Abstract][Full Text] [Related]
17. Development of a high-yield live attenuated H7N9 influenza virus vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets.
Chen Z; Baz M; Lu J; Paskel M; Santos C; Subbarao K; Jin H; Matsuoka Y
J Virol; 2014 Jun; 88(12):7016-23. PubMed ID: 24719414
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of three live attenuated H2 pandemic influenza vaccine candidates in mice and ferrets.
Chen GL; Lamirande EW; Cheng X; Torres-Velez F; Orandle M; Jin H; Kemble G; Subbarao K
J Virol; 2014 Mar; 88(5):2867-76. PubMed ID: 24371061
[TBL] [Abstract][Full Text] [Related]
19. Development of high yield reassortants for influenza type B viruses and analysis of their gene compositions.
Le J; Orff EJ; Fulvini AA; Huang L; Onodera S; Pokorny BA; Malewicz A; Primakov P; Bucher DJ
Vaccine; 2015 Feb; 33(7):879-84. PubMed ID: 25545595
[TBL] [Abstract][Full Text] [Related]
20. Comparative studies of infectivity, immunogenicity and cross-protective efficacy of live attenuated influenza vaccines containing nucleoprotein from cold-adapted or wild-type influenza virus in a mouse model.
Isakova-Sivak I; Korenkov D; Smolonogina T; Tretiak T; Donina S; Rekstin A; Naykhin A; Shcherbik S; Pearce N; Chen LM; Bousse T; Rudenko L
Virology; 2017 Jan; 500():209-217. PubMed ID: 27829176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
